A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
The Alvin and Lois Lapidus Cancer Institute
Study ID
NCT00333008
Phase
PHASE2
Status
Unknown

Conditions

  • Diffuse Large B Cell Lymphoma
  • Lymphoma, Non-Hodgkin

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Doxil — DRUG
  • Cyclophosphamide — DRUG
  • Vincristine — DRUG
  • Prednisone — DRUG
  • Rituximab — DRUG
  • Pegfilgrastim — DRUG

Study Details

The purpose of this study is to evaluate the feasibility and tolerability of delivering a full dose, on time schedule of dose-dense CDOP-R (cyclophosphamide, doxil, vincristine, prednisone, and rituximab) in NHL.

Key Dates

Start date
May 31, 2006
Status verified
Sep 2006

Study Design

Enrollment
27 participants
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Primary Outcome Measure

Safety assessment: National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTACAE) v3.0

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Sinai Hospital of BaltimoreBaltimoreMaryland21215
Pam Nickoles, RN, BSN
[email protected]
410-601-0729
Judy Bosley, RN, BSN
[email protected]
410-601-4392
Stephen Noga, MD, PhD (PRINCIPAL_INVESTIGATOR)
Northwest Hospital CenterRandallstownMaryland21133
Pam Nickoles, RN, BSN
[email protected]
410-601-0729
Judy Bosley, RN, BSN
[email protected]
410-601-4392
Stephen Noga, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Baltimore, MD

By research site
Sinai Hospital of Baltimore· Baltimore, MDNorthwest Hospital Center· Randallstown, MD

Related Studies